One of our product specialists would be happy to answer your questions.
Subscribe to get priority updates and access to videos, data and patient resources, plus details about us and our offerings.
Register and stay up to date with the latest news about QUVIVIQ™▼ (daridorexant), chronic insomnia and sleep science. By registering and ticking this box you are confirming you have read and agreed to the Informed Consent and Privacy Policy and you herewith consent to the processing of your personal data in line therewith.
One of our product specialists would be happy to answer your questions.
One of our product specialists would be happy to answer your questions.
4.5 hours CPD.
Join us at Pulse LIVE Glasgow, a free event tailored for GPs and trainees, on 23 October 2025 at The SEC in Glasgow. This in-person conference offers a comprehensive programme that meets CPD requirements, covering the latest clinical updates, career development workshops policy updates and more.
Attendees can expect expert led-sessions covering various clinical topics such as cardiology, physical activity and diabetes.
Pulse 365 Live events are specifically created for GMC-registered GPs and trainees. Taking place in London, Birmingham, Liverpool, Belfast and Newcastle, you won’t have far to travel for your local event.
Please visite the Pulse 365 event page for more details and registration.
1 – QUVIVIQ™ Idorsia Pharmaceuticals Ltd, Summary of Product Characteristics.
2 – Roch C, et al. Psychopharmacology. 2021; 238(10): 2693–2708.
3 – NICE Clinical Knowledge Summary (CKS) Insomnia: Scenario: Managing long-term insomnia (more than 3 months duration). Available at: https://cks.nice.org.uk/topics/insomnia/management/managing-insomnia/. Updated June 2024. Accessed July 2024.
4 – Mignot E, et al. Lancet Neurol. 2022; 21(2): 125–139.
This information is intended for UK healthcare professionals.
Adverse events must be reported. Healthcare professionals are asked to report any suspected adverse reactions via http://www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in Google play or Apple App store. Adverse events should also be reported to ds.safety.uk@idorsia.com.
This information is intended for UK Healthcare Professionals only.
By entering this site you are confirming that you are a UK Healthcare Professional.
UK-DA-00217 | Date of preparation: October 2023
Copyright © 2023 Idorsia Pharmaceuticals Ltd
You will now be redirected to an independent third party site that is maintained outside of this website, where all Idorsia Pharmaceuticals Ltd UK’s medicines can be found: the electronic Medicines Compendium (eMC)
UK-DA-00439 | Date of preparation: May 2024
Gain access to resources on chronic insomnia
Fill in the form below to get instant access to this resource and unlock our full library of downloadable materials.
UK-DA-00445 | Date of preparation: May 2024
Confirming your contact information and preferences means that you agree that we, Idorsia, manage your personal data in our Client Relationship Management system to document, customise, plan, and conduct our interactions with you and, to analyse and segment your interactions, interests, preferences, and scientific activities in order to interact with you in a way we think is most relevant to you.
It also means that you agree that we will send you Idorsia standard or personalised medical, company or product related information and material via email based on your choices and on what we think is of interest to you. You further consent that we process your personal data for this.
For more information about us, our processing of your personal data and your rights, please see our Privacy Notice.
You already have an account?
Register to get access to: